Mylan N.V.’s (MYL) Overweight Rating Reaffirmed at J P Morgan Chase & Co
Mylan N.V. (NASDAQ:MYL)‘s stock had its “overweight” rating reaffirmed by investment analysts at J P Morgan Chase & Co in a report issued on Friday. They currently have a $48.00 price target on the stock, up from their previous price target of $44.00. J P Morgan Chase & Co’s target price suggests a potential upside of 25.39% from the company’s previous close.
Other equities analysts have also issued reports about the stock. Cowen and Company restated a “hold” rating and issued a $30.00 price objective (down from $43.00) on shares of Mylan N.V. in a report on Wednesday, August 9th. Royal Bank Of Canada restated a “sector perform” rating and issued a $32.00 price objective (down from $33.00) on shares of Mylan N.V. in a report on Thursday, August 10th. Citigroup Inc. upgraded shares of Mylan N.V. from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $36.00 to $42.00 in a report on Wednesday, August 16th. Wells Fargo & Company set a $32.00 price objective on shares of Mylan N.V. and gave the stock a “hold” rating in a report on Wednesday. Finally, UBS AG restated a “buy” rating and issued a $46.00 price objective on shares of Mylan N.V. in a report on Thursday. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $41.99.
Shares of Mylan N.V. (NASDAQ MYL) traded up 0.98% during trading on Friday, hitting $38.29. 6,282,197 shares of the stock were exchanged. Mylan N.V. has a one year low of $29.39 and a one year high of $45.87. The company has a market cap of $20.53 billion, a price-to-earnings ratio of 30.95 and a beta of 1.30. The stock’s 50 day moving average price is $31.86 and its 200-day moving average price is $36.48. Mylan N.V. also was the recipient of unusually large options trading activity on Wednesday. Stock investors bought 10,562 put options on the stock. This represents an increase of 461% compared to the average volume of 1,883 put options.
Mylan N.V. (NASDAQ:MYL) last issued its quarterly earnings data on Wednesday, August 9th. The company reported $1.10 EPS for the quarter, missing the consensus estimate of $1.18 by ($0.08). Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The company had revenue of $2.96 billion during the quarter, compared to analyst estimates of $3 billion. During the same quarter in the prior year, the company posted $1.16 earnings per share. The business’s revenue was up 15.7% compared to the same quarter last year. On average, analysts predict that Mylan N.V. will post $4.57 EPS for the current year.
Several large investors have recently made changes to their positions in MYL. Harvest Management purchased a new stake in shares of Mylan N.V. in the 3rd quarter valued at approximately $3,462,000. Meag Munich Ergo Kapitalanlagegesellschaft purchased a new stake in shares of Mylan N.V. in the 3rd quarter valued at approximately $3,268,000. Eagle Asset Management increased its position in shares of Mylan N.V. by 85.5% in the 3rd quarter. Eagle Asset Management now owns 752,812 shares of the company’s stock valued at $30,308,000 after purchasing an additional 347,018 shares during the last quarter. Water Island Capital increased its position in shares of Mylan N.V. by 817.9% in the 3rd quarter. Water Island Capital now owns 370,088 shares of the company’s stock valued at $14,900,000 after purchasing an additional 329,770 shares during the last quarter. Finally, Janus Capital Management increased its position in shares of Mylan N.V. by 1,608.1% in the 3rd quarter. Janus Capital Management now owns 687,099 shares of the company’s stock valued at $27,663,000 after purchasing an additional 646,874 shares during the last quarter. 71.97% of the stock is currently owned by institutional investors.
Mylan N.V. Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.